<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

7th Annual Symposium:

Advancing Drug Discovery for Oncology

Date: Thursday, November 3, 2022 | 10:00am- 3:30 pm

Location: Hilton Torrey Pines, San Diego

The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically-predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.

This symposium will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross discipline discussions on current techniques and how to move forward with future approaches.

Register Now

Registration for the event is required. Attendance for the symposium is free and lunch will be served, but spaces are limited. We encourage you to register early


Speakers

Gunnar Kauffman Ph.D.

Chief Scientific Officer, Oncternal Therapeutics

Talk Title: Eye of the Beholder: ROR1 as Ideal Target for Immunotherapies?

Elena Brin Ph.D.

Chief Scientific Officer, Athae Bio

Talk Title: Combining Direct Cancer Cell Targeting/Killing with TIL Engagement for a Multipronged Approach to Cancer Treatment

Carine Bossard Ph.D.

Director, Tumor Biology, Biosplice Therapeutics

Talk Title: The Pan-CLK/DYRK Inhibitor Cirtuvivint (SM08502) Selectively Disrupts Alternative Splicing (AS) and Has Broad Anti-tumor Activity in Preclinical Models

James Ernst Ph.D.

Executive Director, Head of Protein Sciences & Technology, Head of Development Sciences at Xencor

Talk Title: Modulating the Immune System with Bispecific Antibodies and Engineered Cytokines

Shivani Malik Ph.D.

Associate Director, Kura Oncology, Inc.

Talk Title: Tipifarnib Potentiates the Antitumor Effects of PI3Kα Blockade in HNSCC via Convergent Inhibition of mTOR Activity

Dean Campbell Ph.D.

Senior Director, Scientific Engagement, Crown Bioscience

Talk Title: Identifying Clinical Candidates with Cancer Organoids

Lars Engstrom Ph.D.

Principal Scientist, Mirati Therapeutics

Talk Title: Enabling a Parallel Translational Biology Strategy for MRTX1719, a Selective PRMT5•MTA Complex Inhibitor for MTAP/CDKN2A Deleted Cancers

Share This

RESERVE MY SEAT

Your privacy is important to us.
We'll never share your information.

Attend Our NorCal Symposium